Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Impact · against what's priced in

Equillium's update provides a concrete catalyst with the Q4 2026 initiation of the EQ504 Phase 1 study and an expected data readout six months later. The substantial cash runway into 2029 significantly lowers the immediate risk of dilutive financing, creating a clearer path to a clinical proof-of-concept milestone.

EQ+0.60

No priced-in read yet